Arch Therapeutics, Inc. (ARTH) financial statements (2022 and earlier)

Company profile

Business Address 235 WALNUT STREET, SUITE 6
FRAMINGHAM, MA 01702
State of Incorp. NV
Fiscal Year End September 30
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,088 9592,1804,6675,994
Cash and cash equivalents1,088 9592,1804,6675,994
Inventory, net of allowances, customer advances and progress billings1,093 968347  
Inventory1,093 968347  
Prepaid expense    152 
Other undisclosed current assets354 216363 85
Total current assets:2,536 2,1432,8904,8196,079
Noncurrent Assets
Property, plant and equipment4 59177
Other noncurrent assets4 4444
Total noncurrent assets:8 8132111
TOTAL ASSETS:2,544 2,1512,9024,8406,090
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities749 342534161265
Accounts payable749 342534161265
Debt  37   
Derivative instruments and hedges, liabilities1,000     
Other undisclosed current liabilities204 267180127169
Total current liabilities:1,952 646714288434
Noncurrent Liabilities
Liabilities, other than long-term debt1,207 2,3162,9963,1923,430
Derivative instruments and hedges, liabilities1,207 2,3162,9963,1923,430
Other undisclosed noncurrent liabilities1,807 689   
Total noncurrent liabilities:3,015 3,0052,9963,1923,430
Total liabilities:4,967 3,6523,7103,4803,864
Stockholders' equity
Stockholders' equity attributable to parent(2,424) (1,500)(807)1,3602,227
Common stock237 193173160150
Additional paid in capital48,687 41,86337,88535,51731,580
Accumulated deficit(51,347) (43,556)(38,865)(34,317)(29,503)
Total stockholders' equity:(2,424) (1,500)(807)1,3602,227
TOTAL LIABILITIES AND EQUITY:2,544 2,1512,9024,8406,090

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
Revenues
(Other undisclosed Revenues)
(4)     
Cost of revenue
(Other undisclosed Cost of revenue)
(33)     
Gross profit:(27)     
Operating expenses(4,876) (5,371)(6,372)(7,450)(7,303)
Operating loss:(4,903) (5,371)(6,372)(7,450)(7,303)
Nonoperating expense
(Other undisclosed Nonoperating expense)
(40)     
Interest and debt expense(121)    (131)
Loss before gain (loss) on sale of properties:(5,064) (5,371)(6,372)(7,450)(7,434)
Other undisclosed net income178 679   
Net loss:(4,886) (4,691)(6,372)(7,450)(7,434)
Other undisclosed net income (loss) attributable to parent40  1,8242,636(355)
Net loss available to common stockholders, diluted:(4,845) (4,691)(4,548)(4,814)(7,789)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
Net loss:(4,886) (4,691)(6,372)(7,450)(7,434)
Comprehensive loss, net of tax, attributable to parent:(4,886) (4,691)(6,372)(7,450)(7,434)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: